What consideration has the Minister given to Ruxolitinib being available for the treatment of myelofibrosis for those aged under 65?
Answered by Minister for Health and Social Services | Answered on 21/11/2023
In March 2016, NICE published guidance recommending Ruxolitinib (Jakavi) as a possible treatment for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only, if they have intermediate‑2 or high-risk disease.
In line with directions to the NHS in Wales, health boards should make Ruxolitinib available where clinically appropriate in accordance with NICE’s guidance.